Abstract

Multi-functional cysteine-targeting covalent warheads possess significant therapeutic potential in medicinal chemistry and chemical biology. Herein, we present novel unsaturated and asymmetric ketone (oxazolinosene) scaffolds that selectively conjugate cysteine residues of peptides and bovine serum albumin under normal physiological conditions. This unsaturated saccharide depletes GSH in NCI-H1299 cells, leading to anti-tumor effects in vitro. The acetyl group of the ketal moiety on the saccharide ring can be converted to other carboxylic acids in a one-pot synthesis. In this way, the loaded acid can be click-released during cysteine conjugation, making the oxazolinosene a potential multifunctional therapeutic agent. The reaction kinetic model for oxazolinosene conjugation to GSH is well established and was used to evaluate oxazolinosene reactivity. The aforementioned oxazolinosenes were stereoselectively synthesized via a one-step reaction of nitriles with saccharides and conveniently converted into a series of α, β-unsaturated ketone N-glycosides as prevalent synthetic building blocks. The reaction mechanisms of oxazolinosene synthesis were investigated through calculations and validated with control experiments. Overall, these oxazolinosenes can be easily synthesized and developed as cysteine-targeted covalent warheads carrying useful click-releasing groups.

Multifunctional cysteine targeting covalent warheads possess significant therapeutic potential in medicinal chemistry and chemical biology. Here, the authors develop an oxazolinosene scaffold from nitrile groups and saccharides that can selectively conjugate cysteine residues within peptides and proteins under physiological conditions, as well as deplete glutathione in cancer cells.

Details

Title
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
Author
Dong, Sanfeng 1 ; Huang, Hui 2 ; Li, Jintian 3 ; Li, Xiaomei 3 ; Bunu, Samuel Jacob 3 ; Yang, Yun 4 ; Zhang, Yong 5 ; Jia, Qi 4 ; Xu, Zhijian 3   VIAFID ORCID Logo  ; Li, Yingxia 6   VIAFID ORCID Logo  ; Zhou, Hu 7   VIAFID ORCID Logo  ; Li, Bo 8   VIAFID ORCID Logo  ; Zhu, Weiliang 3   VIAFID ORCID Logo 

 Fudan University, School of Pharmacy, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); Chinese Academy of Sciences, State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); Shanghai University of Traditional Chinese Medicine, Shanghai, China (GRID:grid.412540.6) (ISNI:0000 0001 2372 7462) 
 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
 Shanghai University of Traditional Chinese Medicine, Shanghai, China (GRID:grid.412540.6) (ISNI:0000 0001 2372 7462) 
 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309) 
 Fudan University, School of Pharmacy, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Shanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, Shanghai, China (GRID:grid.419093.6) (ISNI:0000 0004 0619 8396) 
 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Peking University, State Key Laboratory of Natural and Biomimetic Drugs, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
Pages
201
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993669
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3102226501
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.